Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	endoplasmic reticulum exit site	CTAGE6 CTAGE1 SEC16A CTAGE15	1.33e-04	42	130	4	GO:0070971
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	PLXNA3 ABCC3 SZT2 PTCH1 FHIP1B ITGB4 CCND3 SLC38A10 EHBP1L1 MAP1S PKD1 OSBPL5 SEC16A SAC3D1 TNFAIP3 MMP17 CRAMP1 SOWAHB	2.15e-07	1105	132	18	35748872
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	BIN1 DIDO1 GATAD2B PASK PHC3 ESYT2 GSE1 MAP1S ATXN7 YLPM1 SEC16A SAC3D1 RERE MN1	1.58e-06	774	132	14	15302935
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	PRUNE2 JADE2 TMPRSS5 SHROOM2 AR INKA2 CCND3 ESYT2 FAM120C ATXN7 FBXO42 OSBPL5 RPRD2 GREB1 RERE ZSWIM4 CRAMP1 LRRC41 INVS	3.68e-06	1489	132	19	28611215
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	SZT2 JADE2 KIAA1549 DIDO1 PASK ST6GAL2 OSBPL5 RPRD2 BSN EDEM1 CRAMP1	6.01e-06	529	132	11	14621295
Pubmed	Effects of 1,25-dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells.	AR VDR	1.43e-05	2	132	2	12532336
Pubmed	A Structure-Activity Relationship Study of Bis-Benzamides as Inhibitors of Androgen Receptor-Coactivator Interaction.	AR PELP1	1.43e-05	2	132	2	31370197
Pubmed	Cyclin D3 interacts with vitamin D receptor and regulates its transcription activity.	CCND3 VDR	1.43e-05	2	132	2	16105657
Pubmed	Polycystin-1 Is a Crucial Regulator of BIN1 Expression and T-Tubule Remodeling Associated with the Development of Dilated Cardiomyopathy.	BIN1 PKD1	1.43e-05	2	132	2	36614108
Pubmed	ARF represses androgen receptor transactivation in prostate cancer.	CDKN2A AR	1.43e-05	2	132	2	23449888
Pubmed	The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.	CDKN2A TNFAIP3	1.43e-05	2	132	2	25024217
Pubmed	Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5.	MAP1S RASSF1	1.43e-05	2	132	2	15753381
Pubmed	Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids.	ABCC3 VDR	1.43e-05	2	132	2	15824121
Pubmed	Targeting p16-induced senescence prevents cigarette smoke-induced emphysema by promoting IGF1/Akt1 signaling in mice.	CDKN2A TYR	1.43e-05	2	132	2	31428695
Pubmed	Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk.	AR VDR	1.43e-05	2	132	2	17010601
Pubmed	A strategy to study tyrosinase transgenes in mouse melanocytes.	CDKN2A TYR	1.43e-05	2	132	2	15826307
Pubmed	An endothelial cell genetic screen identifies the GTPase Rem2 as a suppressor of p19ARF expression that promotes endothelial cell proliferation and angiogenesis.	CDKN2A REM2	1.43e-05	2	132	2	18056257
Pubmed	Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.	AR VDR	1.43e-05	2	132	2	15754350
Pubmed	The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.	CDKN2A AR	1.43e-05	2	132	2	32330514
Pubmed	Involvement of p16 and PTCH in pathogenesis of melanoma and basal cell carcinoma.	CDKN2A PTCH1	1.43e-05	2	132	2	19287961
Pubmed	RASSF1A Enhances Chemosensitivity of NSCLC Cells Through Activating Autophagy by Regulating MAP1S to Inactivate Keap1-Nrf2 Pathway.	MAP1S RASSF1	1.43e-05	2	132	2	33442234
Pubmed	Testing in mice the hypothesis that melanin is protective in malaria infections.	TYR VDR	1.43e-05	2	132	2	22242171
Pubmed	GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance.	AR GREB1	1.43e-05	2	132	2	30644358
Pubmed	Role of corticotropin-releasing hormone family peptides in androgen receptor and vitamin D receptor expression and translocation in human breast cancer MCF-7 cells.	AR VDR	1.43e-05	2	132	2	22494987
Pubmed	Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer.	AR VDR	1.43e-05	2	132	2	16425262
Pubmed	Duplicated zinc finger protein genes on the proximal short arm of the human X chromosome: isolation, characterization and X-inactivation studies.	ZXDA ZXDB	1.43e-05	2	132	2	8268913
Pubmed	Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.	CDKN2A AR	1.43e-05	2	132	2	30677079
Pubmed	Molecular basis of the extreme dilution mottled mouse mutation: a combination of coding and noncoding genomic alterations.	TYR P2RX2	1.43e-05	2	132	2	15572362
Pubmed	Cyclin D3 action in androgen receptor regulation and prostate cancer.	AR CCND3	1.43e-05	2	132	2	18084330
Pubmed	Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.	CDKN2A RASSF1	1.43e-05	2	132	2	15447998
Pubmed	DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients.	CDKN2A RASSF1	1.43e-05	2	132	2	23128528
Pubmed	A novel DFNB31 mutation associated with Usher type 2 syndrome showing variable degrees of auditory loss in a consanguineous Portuguese family.	WHRN EYS	1.43e-05	2	132	2	21738389
Pubmed	Promoter methylations of RASSF1A and p16 is associated with clinicopathological features in lung cancers.	CDKN2A RASSF1	1.43e-05	2	132	2	27072261
Pubmed	Associations between androgen and Vitamin D receptor microsatellites and postmenopausal breast cancer.	AR VDR	1.43e-05	2	132	2	17855696
Pubmed	Association between polymorphisms of the androgen and vitamin D receptor genes with prostate cancer risk in a Mexican population.	AR VDR	1.43e-05	2	132	2	17569297
Pubmed	A new murine lymphocyte alloantigen, Ly-21.2, mapping to the seventh chromosome.	ITGAL TYR	1.43e-05	2	132	2	6802749
Pubmed	Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts.	CDKN2A DIDO1 RASSF1	1.89e-05	14	132	3	26201719
Pubmed	Human transcription factor protein interaction networks.	CDKN2A DDX31 TRIP6 WDR33 DIDO1 GATAD2B PHC3 GSE1 ATXN7 YLPM1 DDX54 SEC16A NHLH1 RPRD2 RERE EN1 SENP5	3.05e-05	1429	132	17	35140242
Pubmed	Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.	BIN1 PPFIA4 EXTL1 SHROOM2 DLGAP3 PKD1 OSBPL5 GRIP2	3.93e-05	329	132	8	17474147
Pubmed	Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.	AR PELP1	4.28e-05	3	132	2	15466214
Pubmed	Restoring multidrug resistance-associated protein 3 attenuates cell proliferation in the polycystic kidney.	ABCC3 PKD1	4.28e-05	3	132	2	25143454
Pubmed	Vitamin D receptor variants and the malignant melanoma risk: a population-based study.	CDKN2A VDR	4.28e-05	3	132	2	19679055
Pubmed	[Analysis of the association of polymorphic variants of SYP1A2, GSTT1,GSTM1, GSTP1, XRCC1, XRCC3, AR and VDR genes with predisposition to the development of prostate cancer].	AR VDR	4.28e-05	3	132	2	30695589
Pubmed	Differing tumor-suppressor functions of Arf and p53 in murine basal cell carcinoma initiation and progression.	CDKN2A PTCH1	4.28e-05	3	132	2	28263978
Pubmed	[Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].	AR VDR	4.28e-05	3	132	2	15061984
Pubmed	Desert hedgehog (Dhh) gene is required in the mouse testis for formation of adult-type Leydig cells and normal development of peritubular cells and seminiferous tubules.	PTCH1 AR	4.28e-05	3	132	2	11090455
Pubmed	Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers.	CDKN2A RASSF1	4.28e-05	3	132	2	20056647
Pubmed	Hedgehog signaling pathway and vitamin D receptor gene variants as potential risk factors in odontogenic cystic lesions.	PTCH1 VDR	4.28e-05	3	132	2	30334169
Pubmed	Cdk6-cyclin D3 activity in murine ES cells is resistant to inhibition by p16(INK4a).	CDKN2A CCND3	4.28e-05	3	132	2	14724578
Pubmed	Precise mapping of the gene for Ly-21.2 on the 7th chromosome.	ITGAL TYR	4.28e-05	3	132	2	7161508
Pubmed	Effects of emodin on the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells.	CDKN2A RASSF1	4.28e-05	3	132	2	25891176
Pubmed	The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes.	ABCC3 TRIP6	4.28e-05	3	132	2	35008510
Pubmed	Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation.	PSEN1 TYR	4.28e-05	3	132	2	16384915
Pubmed	Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.	CDKN2A RASSF1	4.28e-05	3	132	2	18358501
Pubmed	[Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers].	CDKN2A RASSF1	4.28e-05	3	132	2	20360646
Pubmed	Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up.	CDKN2A RASSF1	4.28e-05	3	132	2	17920725
Pubmed	Osteopontin promotes age-related adipose tissue remodeling through senescence-associated macrophage dysfunction.	CDKN2A TYR	4.28e-05	3	132	2	37092554
Pubmed	Establishment of two data mining models of lung cancer screening based on three gene promoter methylations combined with telomere damage.	CDKN2A RASSF1	4.28e-05	3	132	2	27716889
Pubmed	Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes.	TYR VDR	4.28e-05	3	132	2	15210908
Pubmed	Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine.	CDKN2A RASSF1	4.28e-05	3	132	2	19181545
Pubmed	The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.	AR CCND3	4.28e-05	3	132	2	24441043
Pubmed	High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.	CDKN2A AR	4.28e-05	3	132	2	32565323
Pubmed	Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes.	TYR VDR	4.28e-05	3	132	2	11720436
Pubmed	Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.	CDKN2A RASSF1	4.28e-05	3	132	2	28600574
Pubmed	Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin.	PSEN1 ITGAL	4.28e-05	3	132	2	26214837
Pubmed	DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients.	CDKN2A RASSF1	4.28e-05	3	132	2	21115918
Pubmed	RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics.	MAP1S RASSF1	4.28e-05	3	132	2	15205320
Pubmed	Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.	CDKN2A RASSF1	4.28e-05	3	132	2	20800513
Pubmed	Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes.	TYR VDR	4.28e-05	3	132	2	11532853
Pubmed	Inactivation of heat shock factor Hsf4 induces cellular senescence and suppresses tumorigenesis in vivo.	CDKN2A HSF4	4.28e-05	3	132	2	22355043
Pubmed	A census of human transcription factors: function, expression and evolution.	BHLHE41 ZBED2 KIAA1549 ZC3H3 AR HOXA4 MZF1 NHLH1 RERE HSF4 EN1 CRAMP1 VDR	4.44e-05	908	132	13	19274049
Pubmed	Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism.	ABCC3 SZT2 AUP1 GJC2 CCND3 PCED1B SMG8 PELP1 FBXO42 YLPM1 DDX54 SEC16A RERE CRAMP1 SOWAHB LRRC41	4.54e-05	1327	132	16	32694731
Pubmed	Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.	WDR33 DIDO1 GATAD2B GSE1 FAM120C YLPM1 DDX54 GREB1	5.05e-05	341	132	8	32971831
Pubmed	An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase.	CHERP WDR33 GSE1 YLPM1 SEC16A RPRD2	6.75e-05	180	132	6	35198878
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	CHERP WDR33 AR GSE1 YLPM1 RPRD2 RERE	7.75e-05	268	132	7	33640491
Pubmed	Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients.	CDKN2A TYR	8.54e-05	4	132	2	19320745
Pubmed	Gene mapping of mouse IL-4 receptor: the loci of interleukin 4 (IL-4) receptor gene and lymphocyte function associated antigen 1 (LFA-1) gene are closely linked on chromosome 7.	ITGAL TYR	8.54e-05	4	132	2	1680807
Pubmed	Patched1-ArhGAP36-PKA-Inversin axis determines the ciliary translocation of Smoothened for Sonic Hedgehog pathway activation.	PTCH1 INVS	8.54e-05	4	132	2	30598432
Pubmed	Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids.	CDKN2A RASSF1	8.54e-05	4	132	2	19618401
Pubmed	Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor.	AR CCND3	8.54e-05	4	132	2	17698582
Pubmed	Meta-analyses of methylation markers for prostate cancer.	CDKN2A RASSF1	8.54e-05	4	132	2	25053593
Pubmed	Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway.	ITGB4 AR	8.54e-05	4	132	2	27109471
Pubmed	Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.	CDKN2A PTCH1	8.54e-05	4	132	2	11212243
Pubmed	Patterns of gene promoter methylation in squamous cell cancer of the head and neck.	CDKN2A RASSF1	8.54e-05	4	132	2	12082610
Pubmed	DNA methylation markers and early recurrence in stage I lung cancer.	CDKN2A RASSF1	8.54e-05	4	132	2	18337602
Pubmed	Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer's Disease.	BIN1 PSEN1	8.54e-05	4	132	2	35269588
Pubmed	Association between hormonal genetic polymorphisms and early-onset prostate cancer.	AR VDR	8.54e-05	4	132	2	15711606
Pubmed	Coat color dilution in mice because of inactivation of the melanoma antigen MART-1.	CDKN2A TYR	8.54e-05	4	132	2	21943097
Pubmed	Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.	CDKN2A RASSF1	8.54e-05	4	132	2	20535589
Pubmed	Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.	AR VDR	8.54e-05	4	132	2	18281521
Pubmed	Whole Genome DNA Methylation Analysis of Obstructive Sleep Apnea: IL1R2, NPR2, AR, SP140 Methylation and Clinical Phenotype.	NPR2 AR	8.54e-05	4	132	2	26888452
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	CDKN2A DDX31 TRIP6 WDR33 NCKAP5L GSE1 FBXO42 SEC16A BSN TEDC1	8.72e-05	588	132	10	38580884
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	CDKN2A TRIP6 PRSS56 KIAA1549 NCKAP5L ZC3H3 GATAD2B PASK GSE1 FAM120C ATXN7 SEC16A RERE LRRC41	9.22e-05	1116	132	14	31753913
Pubmed	High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men.	BMP2K PTCH1 AR HOXA4 WNT10A TNFAIP3 EN1 VDR	1.13e-04	383	132	8	19453261
Pubmed	The MYO6 interactome reveals adaptor complexes coordinating early endosome and cytoskeletal dynamics.	TRIP6 BMP2K WDR33 FAM120C SEC16A	1.19e-04	125	132	5	29467281
Pubmed	Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis.	CDKN2A PTCH1	1.42e-04	5	132	2	19246386
Pubmed	Identification of mutations from phenotype-driven ENU mutagenesis in mouse chromosome 7.	TYR SAA2	1.42e-04	5	132	2	16180137
Pubmed	Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.	CDKN2A RASSF1	1.42e-04	5	132	2	17523078
Pubmed	Spontaneous mutation in mice provides new insight into the genetic mechanisms that pattern the seminal vesicles and prostate gland.	TYR PLEKHA1	1.42e-04	5	132	2	12666202
Pubmed	Beta-catenin activation is necessary and sufficient to specify the dorsal dermal fate in the mouse.	PTCH1 EN1	1.42e-04	5	132	2	16730693
Pubmed	Genome-wide association meta-analysis identifies new endometriosis risk loci.	CDKN2A GREB1	1.42e-04	5	132	2	23104006
GeneFamily	CTAGE family	CTAGE6 CTAGE1 CTAGE15	4.54e-05	15	86	3	907
GeneFamily	DEAD-box helicases	DDX31 DDX54 DDX53	1.04e-03	42	86	3	499
Coexpression	LI_PROSTATE_CANCER_EPIGENETIC	CDKN2A AR RASSF1 DDX53 VDR	5.02e-07	32	130	5	M10861
ToppCell	TCGA-Endometrium-Primary_Tumor-Endometrial_Adenocarcinoma-Serous_adenocarcinoma\|TCGA-Endometrium / Sample_Type by Project: Shred V9	CDKN2A GRIK5 HOXA4 DLGAP3 C19orf84 WNT10A FBN3	6.05e-07	164	132	7	08c725548e751f815b4df778607270498204b353
ToppCell	wk_15-18-Epithelial-PNS-Early_Schwann\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	PRSS56 PKD1L1 TMPRSS5 GRIP2 BSN MMP17 FBN3	1.26e-06	183	132	7	7e8366ec8117d36cec67f77dcb0e9a6032d87fcb
ToppCell	droplet-Fat-SCAT-30m-Epithelial\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BHLHE41 ABCC3 SZT2 SHROOM2 P2RX2 PKD1 C1orf210	1.46e-06	187	132	7	5fada3c5a58c1890029ccbfff2608b33f8cd2df7
ToppCell	droplet-Fat-SCAT-30m-Epithelial-nan\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BHLHE41 ABCC3 SZT2 SHROOM2 P2RX2 PKD1 C1orf210	1.46e-06	187	132	7	766e808138fc2cd623c2e6d57fcb5c7378da0e03
ToppCell	droplet-Fat-SCAT-30m-Epithelial-epithelial_cell\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BHLHE41 ABCC3 SZT2 SHROOM2 P2RX2 PKD1 C1orf210	1.46e-06	187	132	7	f49d06600060deeb2fc1b1da5b93496535f20104
ToppCell	343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1\|343B / Donor, Lineage, Cell class and subclass (all cells)	CDKN2A FRMD6-AS1 DIDO1 ZC3H3 PCED1B RASSF1	5.54e-06	149	132	6	2a7f71da51c85e04de2123164914122480e60d66
ToppCell	TCGA-Endometrium-Primary_Tumor-Endometrial_Adenocarcinoma-Serous_adenocarcinoma-5\|TCGA-Endometrium / Sample_Type by Project: Shred V9	CDKN2A GRIK5 DLGAP3 ZSWIM4 FBN3 SENP5	7.48e-06	157	132	6	59450e9f580555091b159fbbe0a0756e51bcd9ad
ToppCell	droplet-Limb_Muscle-nan-24m-Myeloid-chondrocyte-like\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARMC9 PTCH1 GPR179 HSF4 VDR TEDC1	8.33e-06	160	132	6	984990be02642a562f0c60ea99c01f005e7c02c2
ToppCell	facs-Marrow-B-cells-24m-Hematologic-Unknown_Progenitor\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CDKN2A NPR2 WNT10A C1QTNF4 EDEM1 HSF4	1.26e-05	172	132	6	65b8935a972bf00b7a10dc2d442128fc0ed78bcb
ToppCell	PND01-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_prolif\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	BHLHE41 DDX31 ITGAL BSN CRAMP1 TEDC1	1.73e-05	182	132	6	57f8b8d7b132f3ad6f2b1e79c3812fe938657d2c
ToppCell	droplet-Lung-30m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l25\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	KIAA1549 GRIK5 ITGB4 HOXA4 C1orf210 HYDIN	1.79e-05	183	132	6	6f8f997ffc9eaebca2683de125b6069d07c07d26
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ABCC3 CCND3 WNT10A PLEKHA1 WFDC5 HYDIN	2.14e-05	189	132	6	aadb7a2de4cbe7f0958651f2739bba430b93f5c1
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ABCC3 CCND3 WNT10A PLEKHA1 WFDC5 HYDIN	2.14e-05	189	132	6	8977f3295b7df7c7474b3f371de90a82ae4bb50c
ToppCell	10x_5'_v1-Non-neoplastic-Lymphoid-CD4/CD8-CD8_NK_sig-F_2\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	PTCH1 ITGAL CCND3 RASSF1 OSBPL5 PLEKHA1	2.78e-05	198	132	6	88bb764b21ca50e56f6c536a2d61d35afd8c3f36
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_submucosal-gland\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	CDKN2A ABCC3 SAA2 SAC3D1 ZSWIM4 PDE11A	2.94e-05	200	132	6	68b0f987c4fb8078675475f4f1e71302f832ef69
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_submucosal-gland-SMG_Duct\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	CDKN2A ABCC3 SAA2 SAC3D1 ZSWIM4 PDE11A	2.94e-05	200	132	6	1b527bebbca1ef8c52449e40beb9358e37494e04
Drug	Primidone [125-33-7]; Down 200; 18.4uM; MCF7; HT_HG-U133A	WHRN PLXNA3 BIN1 IQSEC2 ITGB4 EHBP1L1 KCTD2 GAST RERE	2.25e-06	198	131	9	3402_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	TRIP6 JADE2 AR GSE1 MZF1 RASSF1 GREB1 LRRC41	9.88e-06	180	131	8	4821_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A	BHLHE41 BIN1 DDX31 JADE2 DIDO1 MZF1 RPRD2 LRRC41	1.16e-05	184	131	8	7555_DN
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A	USB1 PTCH1 SHROOM2 ITGB4 PASK MZF1 FAM120C TNFAIP3	1.21e-05	185	131	8	5585_DN
Drug	genistein; Down 200; 10uM; HL60; HT_HG-U133A	ZNF142 CDC42EP4 TRIP6 BMP2K ITGAL GSE1 MAP1S LRRC41	1.36e-05	188	131	8	1176_DN
Drug	Methotrexate [59-05-2]; Down 200; 8.8uM; PC3; HT_HG-U133A	ABCC3 BIN1 USB1 PASK RASSF1 FBXO42 TNFAIP3 MN1	1.46e-05	190	131	8	6318_DN
Drug	GSK-3beta Inhibitor VIII; Up 200; 10uM; PC3; HT_HG-U133A	ABCC3 BIN1 BMP2K SZT2 JADE2 WDR33 DIDO1 TNFAIP3	1.46e-05	190	131	8	7070_UP
Drug	Sulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; PC3; HT_HG-U133A	WHRN USB1 SZT2 PPFIA4 IQSEC2 GRIK5 ZC3H3 PASK	1.64e-05	193	131	8	4322_UP
Drug	17-DMAG; Up 200; 0.1uM; PC3; HT_HG-U133A	WHRN PRUNE2 ABCC3 USB1 IQSEC2 DIDO1 ALPK3 TNS4	1.70e-05	194	131	8	1213_UP
Drug	Sulmazole [73384-60-8]; Down 200; 14uM; HL60; HT_HG-U133A	BHLHE41 CDKN2A JADE2 WDR33 LILRB2 ZC3H3 PASK VDR	1.77e-05	195	131	8	2153_DN
Drug	Clebopride maleate [84370-95-6]; Up 200; 8.2uM; HL60; HT_HG-U133A	WHRN NPR2 DDX31 JADE2 WDR33 GRIK5 KCTD2 LRRC41	1.77e-05	195	131	8	1292_UP
Drug	6-Hydroxytropinone [5932-53-6]; Down 200; 25.8uM; MCF7; HT_HG-U133A	WHRN ABCC3 BIN1 SZT2 ZC3H3 EHBP1L1 FAM120C TNFAIP3	1.83e-05	196	131	8	4833_DN
Drug	Piretanide [55837-27-9]; Down 200; 11uM; MCF7; HT_HG-U133A	PLXNA3 NPR2 USB1 BMP2K LILRB2 PHC3 YLPM1 GREB1	1.83e-05	196	131	8	3567_DN
Drug	Procaine hydrochloride [51-05-8]; Down 200; 14.6uM; PC3; HT_HG-U133A	WHRN ABCC3 BIN1 DDX31 USB1 BMP2K ITGB4 ATXN7	1.90e-05	197	131	8	1796_DN
Drug	Gelsemine [509-15-9]; Down 200; 12.4uM; MCF7; HT_HG-U133A	WHRN BIN1 USB1 IQSEC2 GRIK5 INKA2 PHC3 GREB1	1.90e-05	197	131	8	4177_DN
Drug	Dapsone [80-08-0]; Down 200; 16.2uM; MCF7; HT_HG-U133A	WHRN ABCC3 NPR2 USB1 EHBP1L1 MAP1S MZF1 TNFAIP3	1.90e-05	197	131	8	1705_DN
Drug	Prednisone	CDKN2A ABCC3 AR VDR	4.77e-05	35	131	4	ctd:D011241
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	TRIP6 JADE2 DIDO1 ITGB4 MZF1 GREB1 LRRC41	6.55e-05	173	131	7	5987_DN
Drug	5182598; Up 200; 25uM; MCF7; HT_HG-U133A_EA	ABCC3 BIN1 GRIK5 PTCH1 PASK PHC3 RASSF1	7.57e-05	177	131	7	976_UP
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	TRIP6 JADE2 DIDO1 GSE1 RPRD2 GREB1 LRRC41	8.70e-05	181	131	7	6951_DN
Drug	Gabazine [105538-73-6]; Down 200; 10.8uM; MCF7; HT_HG-U133A	USB1 IQSEC2 AR PHC3 EHBP1L1 RASSF1 DDX54	1.18e-04	190	131	7	3253_DN
Drug	Denatonium benzoate [3734-33-6]; Down 200; 9uM; HL60; HT_HG-U133A	BIN1 CDC42EP4 ARMC9 PASK KCTD2 RERE LRRC41	1.22e-04	191	131	7	3123_DN
Drug	Diethylstilbestrol [56-53-1]; Down 200; 15uM; HL60; HT_HG-U133A	BHLHE41 WDR33 PPFIA4 PTCH1 ITGB4 PHC3 MZF1	1.30e-04	193	131	7	2567_DN
Drug	Viomycin sulfate [37883-00-4]; Down 200; 5.2uM; MCF7; HT_HG-U133A	DDX31 JADE2 IQSEC2 MAP1S RASSF1 DDX54 KCTD2	1.34e-04	194	131	7	7036_DN
Drug	Nafronyl oxalate [3200-06-4]; Up 200; 8.4uM; HL60; HT_HG-U133A	CDKN2A LILRB2 PTCH1 ITGB4 YLPM1 KCTD2 LRRC41	1.34e-04	194	131	7	1267_UP
Drug	pioglitazone HCl; Up 200; 10uM; MCF7; HT_HG-U133A	BHLHE41 BIN1 ZBED2 INKA2 HSF4 MMP17 VDR	1.34e-04	194	131	7	7523_UP
Drug	NU1025; Up 200; 100uM; MCF7; HG-U133A	NPR2 BIN1 TMPRSS5 GRIK5 MZF1 FBXO42 PDE11A	1.34e-04	194	131	7	608_UP
Drug	Idoxuridine [54-42-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A	PLXNA3 ZC3H3 ITGB4 RASSF1 FBXO42 DDX54 RERE	1.34e-04	194	131	7	1480_DN
Drug	Homosalate [118-56-9]; Down 200; 15.2uM; PC3; HT_HG-U133A	WHRN BIN1 USB1 EHBP1L1 MAP1S FAM120C SENP5	1.38e-04	195	131	7	4533_DN
Drug	(R)-(+)-Atenolol [56715-13-0]; Up 200; 15uM; MCF7; HT_HG-U133A	BIN1 IQSEC2 GRIK5 ITGB4 EHBP1L1 MAP1S GREB1	1.38e-04	195	131	7	2855_UP
Drug	Phenelzine sulfate [156-51-4]; Down 200; 17uM; MCF7; HT_HG-U133A	ABCC3 BIN1 JADE2 BCAS4 ITGB4 EHBP1L1 VDR	1.38e-04	195	131	7	4360_DN
Drug	Quinidine hydrochloride monohydrate [6151-40-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A	PLXNA3 BMP2K AR EHBP1L1 MZF1 KCTD2 TNFAIP3	1.38e-04	195	131	7	3191_DN
Drug	3-Acetamidocoumarin [779-30-6]; Up 200; 19.6uM; MCF7; HT_HG-U133A	PRUNE2 CDKN2A ITGB4 AR RASSF1 RERE VDR	1.38e-04	195	131	7	7361_UP
Drug	Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; MCF7; HT_HG-U133A	BIN1 CDC42EP4 USB1 LILRB2 PHC3 GREB1 VDR	1.43e-04	196	131	7	6846_DN
Drug	Neomycin sulfate [1405-10-3]; Down 200; 4.2uM; PC3; HT_HG-U133A	BIN1 BMP2K DIDO1 EHBP1L1 MZF1 FBXO42 VDR	1.43e-04	196	131	7	2066_DN
Drug	Ethoxyquin [91-53-2]; Up 200; 18.4uM; PC3; HT_HG-U133A	PRUNE2 ABCC3 NPR2 IQSEC2 PASK NHLH1 TNS4	1.43e-04	196	131	7	4321_UP
Drug	Pimethixene maleate [13187-06-9]; Up 200; 9.8uM; MCF7; HT_HG-U133A	ABCC3 USB1 BMP2K IQSEC2 GRIK5 PHC3 TNFAIP3	1.43e-04	196	131	7	7426_UP
Drug	Cefamandole sodium salt [30034-03-8]; Down 200; 8.2uM; MCF7; HT_HG-U133A	USB1 EHBP1L1 MAP1S MZF1 DDX54 RPRD2 VDR	1.43e-04	196	131	7	4718_DN
Drug	Repaglinide [135062-02-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A	WHRN WDR33 PPFIA4 EHBP1L1 FAM120C HSF4 VDR	1.43e-04	196	131	7	3558_UP
Drug	Nialamide [51-12-7]; Down 200; 13.4uM; MCF7; HT_HG-U133A	CDKN2A BIN1 USB1 GRIK5 PHC3 RERE VDR	1.43e-04	196	131	7	4347_DN
Drug	Methiazole; Down 200; 15uM; MCF7; HT_HG-U133A	ABCC3 NPR2 USB1 JADE2 IQSEC2 RASSF1 HSF4	1.43e-04	196	131	7	3878_DN
Drug	Riboflavine [83-88-5]; Up 200; 10.6uM; HL60; HG-U133A	BIN1 ZNF142 BMP2K AUP1 PASK MZF1 SAC3D1	1.47e-04	197	131	7	1767_UP
Drug	Butacaine [149-16-6]; Down 200; 13uM; HL60; HT_HG-U133A	GRIK5 PTCH1 PASK PHC3 MZF1 KCTD2 RERE	1.47e-04	197	131	7	2728_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HG-U133A	PSEN1 TRIP6 DIDO1 SLC38A10 MZF1 SAC3D1 RPRD2	1.47e-04	197	131	7	1732_DN
Drug	Methylprednisolone, 6-alpha [83-43-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A	ABCC3 BIN1 USB1 ARMC9 ZC3H3 MZF1 FBXO42	1.47e-04	197	131	7	6785_DN
Drug	Folinic acid calcium salt [6035-45-6]; Up 200; 7.8uM; MCF7; HT_HG-U133A	ITGB4 PHC3 MZF1 RASSF1 DDX54 GREB1 RERE	1.47e-04	197	131	7	3442_UP
Drug	Hexestrol [84-16-2]; Up 200; 14.8uM; PC3; HT_HG-U133A	WHRN PRUNE2 CDKN2A LILRB2 ITGAL TNFAIP3 GAST	1.47e-04	197	131	7	5776_UP
Drug	Alprostadil [745-65-3]; Up 200; 11.2uM; MCF7; HT_HG-U133A	WHRN PRUNE2 PLXNA3 BIN1 CDC42EP4 ZC3H3 MAP1S	1.47e-04	197	131	7	7358_UP
Drug	Streptomycin sulfate [3810-74-0]; Down 200; 2.8uM; MCF7; HT_HG-U133A	ABCC3 BIN1 CDC42EP4 LILRB2 MAP1S YLPM1 KCTD2	1.47e-04	197	131	7	7194_DN
Drug	Meticrane [1084-65-7]; Down 200; 14.6uM; PC3; HT_HG-U133A	ITGB4 EHBP1L1 ATXN7 RASSF1 FBXO42 DDX54 LRRC41	1.47e-04	197	131	7	1792_DN
Drug	prochlorperazine dimaleate salt; Down 200; 10uM; PC3; HT_HG-U133A	BIN1 DDX31 CHERP JADE2 SHROOM2 FBXO42 YLPM1	1.47e-04	197	131	7	1215_DN
Drug	Ticarcillin sodium [4697-14-7]; Up 200; 9.4uM; HL60; HT_HG-U133A	PRUNE2 ABCC3 BIN1 BCAS4 PHC3 RERE EN1	1.52e-04	198	131	7	6146_UP
Drug	Cephapirin sodium salt [24356-60-3]; Down 200; 9uM; HL60; HT_HG-U133A	BIN1 JADE2 LILRB2 ITGB4 PHC3 FAM120C RERE	1.52e-04	198	131	7	2730_DN
Drug	Sulfamethazine sodium salt [1981-58-4]; Down 200; 13.4uM; MCF7; HT_HG-U133A	ABCC3 BIN1 USB1 PASK DDX54 RERE SENP5	1.52e-04	198	131	7	3847_DN
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A	BIN1 BMP2K IQSEC2 DIDO1 ARMC9 GRIK5 PHC3	1.52e-04	198	131	7	4367_DN
Drug	Bemegride [64-65-3]; Down 200; 25.8uM; PC3; HT_HG-U133A	WHRN PLXNA3 DDX31 USB1 IQSEC2 PASK ATXN7	1.52e-04	198	131	7	6668_DN
Drug	Norethynodrel [68-23-5]; Down 200; 13.4uM; PC3; HT_HG-U133A	CDKN2A NPR2 DDX31 USB1 BMP2K ZC3H3 KCTD2	1.52e-04	198	131	7	1818_DN
Drug	Orphenadrine hydrochloride [341-69-5]; Down 200; 13uM; MCF7; HT_HG-U133A	BIN1 JADE2 PASK EHBP1L1 RASSF1 HSF4 MMP17	1.52e-04	198	131	7	3883_DN
Drug	Benzbromarone [3562-84-3]; Down 200; 9.4uM; HL60; HT_HG-U133A	DDX31 CDC42EP4 JADE2 ZC3H3 PASK RERE VDR	1.52e-04	198	131	7	1291_DN
Drug	Flecainide acetate [54143-56-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A	NPR2 WDR33 IQSEC2 ZC3H3 EHBP1L1 RERE SENP5	1.52e-04	198	131	7	3843_DN
Drug	Vitamin K2 [11032-49-8]; Down 200; 9uM; MCF7; HT_HG-U133A	WHRN BMP2K PASK FAM120C RASSF1 HSF4 MMP17	1.52e-04	198	131	7	3880_DN
Drug	clotrimazole; Down 200; 50uM; MCF7; HT_HG-U133A_EA	ABCC3 USB1 BMP2K MAP1S DDX54 LRRC41 SENP5	1.52e-04	198	131	7	905_DN
Drug	Bromopride [4093-35-0]; Down 200; 11.6uM; MCF7; HT_HG-U133A	BMP2K SZT2 GRIK5 PHC3 MZF1 GREB1 RERE	1.52e-04	198	131	7	6037_DN
Drug	Isocarboxazid [59-63-2]; Down 200; 17.2uM; HL60; HT_HG-U133A	BHLHE41 USB1 SZT2 ARMC9 PTCH1 PHC3 FAM120C	1.57e-04	199	131	7	2562_DN
Drug	Zoxazolamine [61-80-3]; Up 200; 23.8uM; MCF7; HT_HG-U133A	BHLHE41 ABCC3 IQSEC2 ZC3H3 EHBP1L1 RERE VDR	1.57e-04	199	131	7	2625_UP
Drug	Ribavirin [36791-04-5]; Down 200; 16.4uM; PC3; HT_HG-U133A	DDX31 USB1 BCAS4 GSE1 TNFAIP3 MN1 LRRC41	1.57e-04	199	131	7	7316_DN
Drug	(R)-(+)-Atenolol [56715-13-0]; Down 200; 15uM; MCF7; HT_HG-U133A	DDX31 WDR33 AR PASK PHC3 RERE LRRC41	1.57e-04	199	131	7	2855_DN
Drug	Antazoline hydrochloride [2508-72-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A	BIN1 GRIK5 MAP1S GREB1 TNFAIP3 MN1 VDR	1.57e-04	199	131	7	6775_UP
Drug	Thiethylperazine malate [52239-63-1]; Down 200; 6uM; PC3; HT_HG-U133A	PLXNA3 ABCC3 SZT2 PASK MZF1 FAM120C VDR	1.57e-04	199	131	7	5756_DN
Drug	Nitrofurantoin [67-20-9]; Up 200; 16.8uM; HL60; HT_HG-U133A	CDC42EP4 LILRB2 IQSEC2 PHC3 DDX54 RERE SENP5	1.57e-04	199	131	7	2341_UP
Drug	haloperidol; Up 200; 10uM; MCF7; HT_HG-U133A	WHRN PRUNE2 CDKN2A EXTL1 PTCH1 TNFAIP3 GAST	1.57e-04	199	131	7	5604_UP
Drug	Fluticasone propionate [80474-14-2]; Up 200; 8uM; MCF7; HT_HG-U133A	BIN1 JADE2 PTCH1 ITGB4 EHBP1L1 FAM120C VDR	1.57e-04	199	131	7	7348_UP
Drug	bibutyryl	LIPE GAST	1.96e-04	4	131	2	CID000138508
Drug	AC1N8N2J	GRIK5 PTCH1 ZACN	1.98e-04	20	131	3	CID004346372
Disease	skin melanoma (is_implicated_in)	CDKN2A TYR VDR	2.55e-05	14	124	3	DOID:8923 (is_implicated_in)
Disease	neurotic disorder	TMPRSS5 PTCH1 RASSF1 YLPM1 RERE	6.93e-05	101	124	5	EFO_0004257
Disease	neutrophil count	PRUNE2 CDKN2A BIN1 JADE2 WDR33 IQSEC2 ITGAL CCND3 ATXN7 PKD1 NHLH1 RPRD2 C1orf210 TNFAIP3 RERE HYDIN	2.27e-04	1382	124	16	EFO_0004833
Disease	melanoma (is_implicated_in)	CDKN2A TYR VDR	3.94e-04	34	124	3	DOID:1909 (is_implicated_in)
Disease	basal cell carcinoma (is_marker_for)	PTCH1 VDR	4.82e-04	8	124	2	DOID:2513 (is_marker_for)
Disease	Prostatic Cancer, Castration-Resistant	AR ZNF367	6.19e-04	9	124	2	C3658266
Disease	Prostatic Neoplasms, Castration-Resistant	AR ZNF367	6.19e-04	9	124	2	C3658267
Disease	basal cell carcinoma (is_implicated_in)	PTCH1 VDR	1.12e-03	12	124	2	DOID:2513 (is_implicated_in)
Disease	peak expiratory flow	MXRA8 PAIP1 EYS PKD1 MN1 FBN3 ZNF367 VDR	1.24e-03	498	124	8	EFO_0009718
Disease	basal cell carcinoma	BCAS4 STK35 TYR SEC16A VDR	1.24e-03	189	124	5	EFO_0004193
Disease	inflammatory biomarker measurement, YKL40 measurement	PTCH1 ST6GAL2 VDR	1.30e-03	51	124	3	EFO_0004869, EFO_0004872
Disease	prostate cancer (is_implicated_in)	CDKN2A AR RASSF1 VDR	1.53e-03	117	124	4	DOID:10283 (is_implicated_in)
Disease	Alopecia, Male Pattern	AR VDR	1.77e-03	15	124	2	C4083212
Disease	Androgenetic Alopecia	AR VDR	1.77e-03	15	124	2	C0162311
Disease	Female pattern alopecia (disorder)	AR VDR	1.77e-03	15	124	2	C0263477
Disease	Disorder of eye	WHRN GPR179 TYR EYS INVS	2.06e-03	212	124	5	C0015397
Disease	HETE measurement	GSE1 MAP1S DDX53	2.29e-03	62	124	3	EFO_0801166
Disease	cholangiocarcinoma (is_marker_for)	CDKN2A PRSS56 TNFAIP3	2.50e-03	64	124	3	DOID:4947 (is_marker_for)
Disease	unipolar depression, mood disorder	TMPRSS5 EYS YLPM1 RERE	2.50e-03	134	124	4	EFO_0003761, EFO_0004247
Disease	skin pigmentation measurement	PTCH1 TYR EN1 HYDIN	2.71e-03	137	124	4	EFO_0007009
Disease	osteoporosis (implicated_via_orthology)	AR VDR	2.86e-03	19	124	2	DOID:11476 (implicated_via_orthology)
Disease	Pseudopelade	AR VDR	2.86e-03	19	124	2	C0086873
Disease	Alopecia	AR VDR	2.86e-03	19	124	2	C0002170
Disease	vitiligo (is_implicated_in)	TYR VDR	3.49e-03	21	124	2	DOID:12306 (is_implicated_in)
Disease	rosacea severity measurement	RNF217 SAA2 EHBP1L1 MGAM2	3.49e-03	147	124	4	EFO_0009180
Disease	photoreceptor cell layer thickness measurement	TYR GSE1 YLPM1 MN1	3.58e-03	148	124	4	EFO_0803370
Disease	monocyte count	CDKN2A BMP2K SZT2 JADE2 DIDO1 ARMC9 SHC3 CCND3 GSE1 YLPM1 PKD1 NHLH1 MN1	3.74e-03	1320	124	13	EFO_0005091
Disease	breast cancer (is_implicated_in)	CDKN2A RASSF1 TNFAIP3 VDR	3.75e-03	150	124	4	DOID:1612 (is_implicated_in)
Disease	monocyte percentage of leukocytes	BIN1 JADE2 IQSEC2 ARMC9 SHC3 CCND3 MAP1S SEC16A RERE	3.80e-03	731	124	9	EFO_0007989
Disease	transitional cell carcinoma (is_implicated_in)	CDKN2A RASSF1	3.83e-03	22	124	2	DOID:2671 (is_implicated_in)
Disease	Granulomatous Slack Skin	CDKN2A TNFAIP3	3.83e-03	22	124	2	C0376407
Disease	Lymphoma, T-Cell, Cutaneous	CDKN2A TNFAIP3	4.18e-03	23	124	2	C0079773

Protein segments in the cluster

Peptide	Gene	Start	Entry
PVRVNDGGGSHPSRP	VDR	156	P11473
QPPEAGPQGLHDLGR	ESYT2	721	A0FGR8
HAPRAGPDPRLLGDQ	CCND3	11	P30281
RGSRGPGNPPDHQIT	CTAGE1	526	Q96RT6
REHAPNGPAPLGQRS	CTAGE6	516	Q86UF2
REHAPNGPAPLGQRS	CTAGE15	516	A4D2H0
GRTHLPFAGPREPGN	BHLHE41	451	Q9C0J9
TRPGPNRHEPGGRDP	GSE1	546	Q14687
NRHEPGGRDPPQHFG	GSE1	551	Q14687
ARSEGVPGAPGQPTH	ALPK3	656	Q96L96
GQQPLPRRPGHDDGQ	CDKN2A	56	Q8N726
PRRPGHDDGQRPSGG	CDKN2A	61	Q8N726
SLVGSDAGPGPRHQP	C1QTNF4	186	Q9BXJ3
AGHSQPGAVRRPPRG	C19orf84	91	I3L1E1
SGLPGRNGQRHAPEI	NPR2	916	P20594
NPHGSDARGIPSLGP	FBN3	381	Q75N90
PGEFGNHRPKGALRP	BMP2K	401	Q9NSY1
NHRPKGALRPGNGPE	BMP2K	406	Q9NSY1
LVPGRGHRFQPAGPA	RASSF1	46	Q9NS23
QPRADHQRGLVPPGA	QRICH2	576	Q9H0J4
HQRGLVPPGADQRGL	QRICH2	581	Q9H0J4
GQGRPVPRRHLGPSE	ABCC3	916	O15438
PSAPSGNLPHRGLQG	KIAA1549	1891	Q9HCM3
PAQGDGHSLPPIARR	FBXO42	606	Q6P3S6
ASRGPGHRIPQGANL	FHIP1B	11	Q8N612
APNGQGCLHPGDPRL	PASK	1306	Q96RG2
GLLATHPRPGQERPG	MAP1S	486	Q66K74
RGLGNPEGHPNAGRS	EYS	2591	Q5T1H1
AGSESPHPGRRTPGN	NCKAP5L	626	Q9HCH0
ALPQGEHARSPQPRG	GREB1	1151	Q4ZG55
PFPGTGEHRRGENPP	INKA2	261	Q9NTI7
LPRNHNGPGFRDQDP	MGAM2	631	Q2M2H8
NVPQEGPSGPERGHH	GPR179	1006	Q6PRD1
QGRPGTHERPGAKPR	GJC2	406	Q5T442
PTINEGDRLGPPHGA	PPFIA4	6	O75335
GDEPLQRPVTPGGHR	ARMC9	646	Q7Z3E5
RAPRRGAGGHPQFAP	IQSEC2	1341	Q5JU85
PEGLGQPREPVLHRG	BSN	2516	Q9UPA5
DRGQGASRPHAPGTP	DDX54	801	Q8TDD1
HRPLPETGRGGRPQV	C1orf210	66	Q8IVY1
PLNNGHREDPAPGLL	JADE2	551	Q9NQC1
LGRPQPRAQGEHPDE	PLXNA3	1086	P51805
RHSQGQGALGPRPSL	PDE11A	41	Q9HCR9
PGPRVEGPPQANRNH	PCED1B	271	Q96HM7
AHGPGAPEARARVPQ	EHBP1L1	196	Q8N3D4
QHPAGAVGPEPTDRG	LILRB2	501	Q8N423
QGEDGSPQAHRRGPT	AR	91	P10275
GNLRPHGDNRTAGRP	GATAD2B	81	Q8WXI9
GRGPKQPEREPQPGH	OTUD7A	81	Q8TE49
NAPGEPGGRPLQHSL	DDX31	806	Q9H8H2
PRLLPGPENHRAGSN	PELP1	721	Q8IZL8
AGRDPVHPLGTRAPG	EN1	151	Q05925
RSATPGPPGEHLVNG	ITGB4	1431	P16144
NQSLGHRGRRPSGPD	PHC3	831	Q8NDX5
RHDQSGRGPPTGSPA	ATXN7	771	O15265
FPNGAGPAERARHQP	PAIP1	31	Q9H074
ARVLGQAPPEPGHRS	P2RX2	396	Q9UBL9
GPASHHRRQLGPQGP	GAST	51	P01350
RGPEPGEPGRKDLQH	NHLH1	46	Q02575
PHEPDDQRQVPLGGR	HYDIN	2491	Q4G0P3
PLRHAASPSPQRQGG	DACT2	356	Q5SW24
PHGFNGQPPHMRRQG	CHERP	616	Q8IWX8
HTAPPRLQEAGGPTG	LINC01599	226	Q8WXQ3
GRQDPRPGSLPTALH	CRAMP1	711	Q96RY5
GRSFQRHASEPQPGP	DLGAP3	706	O95886
RSRGFAGLHPIPPQG	FAM120C	941	Q9NX05
EAVPRRNGAAGPHSP	CDC42EP4	161	Q9H3Q1
TARGPHPNQFEGPRG	DIDO1	1936	Q9BTC0
PGRNHGLPGSLRQPD	BCAS4	11	Q8TDM0
PQTRHFPGRGADPAL	FRMD6-AS1	91	P0C7T7
NPIHCRGRGPDRGDP	EDEM1	156	Q92611
PETNLGLSPHRARGP	HSF4	246	Q9ULV5
FGHQGPRAAGSREPP	DDX53	36	Q86TM3
GGAGSPPQAHLPSER	CDH22	716	Q9UJ99
SAHGGPQRLLDDPGP	GRIK5	901	Q16478
VRPDGPAHRGGLQPF	GRIP2	971	Q9C0E4
RVNHEPEPAGGATPG	BIN1	311	O00499
GVLPGPRDHGGPTQR	RPRD2	1341	Q5VT52
PRDHGGPTQRDLNGP	RPRD2	1346	Q5VT52
ARGAGPHPRQPAFQG	SAC3D1	216	A6NKF1
LGPGDRGLHPRPQAV	SLC38A10	596	Q9HBR0
QQPQLPHAGGGREPT	HOXA4	56	Q00056
PLRGGAQTEAPHGPN	PKD1L1	2031	Q8TDX9
RAPPPGAQLLHGGLQ	PRR18	206	Q8N4B5
LRQRHVAQPGPGPGE	LIPE	131	Q05469
HGNQSSPELGPPRLR	PKD1	3736	P98161
QGPGLERKGHHPLNP	PRSS56	581	P0CW18
RPNEGSDGSRHPGVP	INVS	706	Q9Y283
PRGHGRPAAAVAQPL	KCTD2	41	Q14681
GSPGPRHERSGPDQR	OSBPL5	746	Q9H0X9
GPQRPGNLPDFHSSG	MN1	166	Q10571
RHQDPGDPGPGIRTE	SMG8	81	Q8ND04
PPDGQRRHRPESGSG	SZT2	2871	Q5T011
NVGGGPPHRVPRSLD	PRUNE2	1476	Q8WUY3
SGRDPNHFRPAGLPE	SAA2	106	P0DJI9
HPEPLSNGRPQGNSR	PSEN1	46	P49768
RVDHPSQRDNPGVPG	LRRC41	556	Q15345
GPRAPPGQHDQSRSE	MMP17	541	Q9ULZ9
PHLDSGSLPPGRQGQ	PTCH1	1286	Q13635
RPPRGAPHASDQVLG	SHC3	136	Q92529
GPRAQSPGSPLHARG	SHROOM2	1031	Q13796
PGGLDARQALPRAHP	ST6GAL2	71	Q96JF0
PQPHGGALRQQEGDR	WHRN	251	Q9P202
PPQHLSEAGRGPVGS	RERE	161	Q9P2R6
GHPEPPRPQGDSARA	RNF217	26	Q8TC41
GRHGGLSPQPSQRIE	ITGAL	556	P20701
PSRSPQGLRNRGDGH	SOWAHB	451	A6NEL2
LPEAHPLRGGAPGQL	EXTL1	201	Q92935
PLRGGAPGQLRQHSP	EXTL1	206	Q92935
GQGSPLPGQPRSQDH	C17orf64	191	Q86WR6
GPGPERLFDSHRLPG	AUP1	6	Q9Y679
GPTERVHDGRPGALP	WFDC5	146	Q8TCV5
GRVHRGPDSPAGQVP	ZXDB	26	P98169
QGPEHHRNGGPLIPK	SENP5	201	Q96HI0
ARSRRQPGPGADHPQ	STK35	66	Q8TDR2
QHTQGLPADRGGLRP	TRIP6	76	Q15654
RGRGGEHGPQVPLSQ	TRIP6	236	Q15654
AVRPLHGARGGQPPV	ZC3H3	91	Q8IXZ2
GQAGQRQDPRPHGPQ	ZBED2	116	Q9BTP6
QRMGPGAHRGEPAPE	TNFAIP3	741	P21580
HPRQSGPGAPNLDRF	SEC16A	1026	O15027
NQGRGHQRPLPPSEG	TNS4	206	Q8IZW8
LPENRGRQAGVPHAP	UROC1	16	Q96N76
DGGPAQPHGPHRLVR	TEDC1	421	Q86SX3
GTPEGPLRRNPGNHD	TYR	291	P14679
GPGIFRAEPGDQQHP	TMPRSS5	21	Q9H3S3
RGRNHAGGQRPDPGS	REM2	281	Q8IYK8
VPRDGHQHGPMPRGN	nan	156	Q6ZUG5
PGDGSHRRGQSPLPR	USB1	26	Q9BQ65
EGNRPDGPRPRYEGH	YLPM1	786	P49750
PAPRGEQREHGNPGP	ZACN	331	Q401N2
DRGDSGPNAPHRTPQ	ZNF70	121	Q9UC06
GRVHRGPDSPAGQVP	ZXDA	26	P98168
NQLSARPEGPGHEPG	ZNF142	631	P52746
RPHNRNGGQLEPGPA	WNT10A	301	Q9GZT5
PEHGPERGPFRGGQD	WDR33	981	Q9C0J8
AEHSGLRGRGAPPPA	ZNF367	101	Q7RTV3
QRGPGRSASSEHPPG	PLEKHA1	291	Q9HB21
HLSGNIREPGSPGEP	ZSWIM4	121	Q9H7M6
SGAPGPDPTLARGHN	MXRA8	311	Q9BRK3
LQHQRIHGDPPGPGA	MZF1	456	P28698